Until now antigen tests had only gauged the presence of antibodies, not their quantity
A new crop of Covid-19 antibody tests is set to play an integral part in the development of an effective vaccine.
Siemens Healthineers is the first company to gain US Food and Drug Administration clearance for a test that assesses the quantity of long-lasting antibodies in the blood. Earlier antigen tests could only tell whether antibodies were present.
Swiss giant Roche is following up with its version.
Quantity over quality
The level of the body’s response is important in determining whether patients will develop immunity. It is also key to determining the effectiveness of vaccines as developers bring promising candidates through the sequential vaccine trials, documented here.
- سيعجبك أيضاً